Josh Jennings
Stock Analyst at Morgan Stanley
(2.62)
# 2,211
Out of 4,964 analysts
14
Total ratings
54.55%
Success rate
18.14%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Josh Jennings
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCBO Docebo | Maintains: Overweight | $49 → $53 | $31.33 | +69.17% | 5 | Nov 10, 2023 | |
| PODD Insulet | Maintains: Outperform | $350 → $300 | $337.60 | -11.14% | 3 | Aug 9, 2023 | |
| BFLY Butterfly Network | Initiates: Outperform | $20 | $1.63 | +1,126.99% | 1 | Jun 21, 2021 | |
| MDWD MediWound | Initiates: Outperform | $63 | $16.80 | +275.00% | 1 | Sep 28, 2017 | |
| CTSO Cytosorbents | Initiates: Outperform | $7 | $0.94 | +644.68% | 1 | Jun 7, 2017 | |
| EW Edwards Lifesciences | Maintains: Outperform | $43 → $40 | $81.23 | -50.76% | 3 | Dec 7, 2016 |
Docebo
Nov 10, 2023
Maintains: Overweight
Price Target: $49 → $53
Current: $31.33
Upside: +69.17%
Insulet
Aug 9, 2023
Maintains: Outperform
Price Target: $350 → $300
Current: $337.60
Upside: -11.14%
Butterfly Network
Jun 21, 2021
Initiates: Outperform
Price Target: $20
Current: $1.63
Upside: +1,126.99%
MediWound
Sep 28, 2017
Initiates: Outperform
Price Target: $63
Current: $16.80
Upside: +275.00%
Cytosorbents
Jun 7, 2017
Initiates: Outperform
Price Target: $7
Current: $0.94
Upside: +644.68%
Edwards Lifesciences
Dec 7, 2016
Maintains: Outperform
Price Target: $43 → $40
Current: $81.23
Upside: -50.76%